Evicenter
MarkdownMedical informationP&T meetings
Onvuzosiran (ADX-324)

Prophylaxis of hereditary angioedema attacks

Launch
Not announced
Last updated
119 sources

Section 4 of 6

Clinical evidence

267 evidence topics · 52 sources

Study summaries

STOP-HAE

Objective
Location and study date
UK research ethics committee opinion
Study design
Registry design details
Eligibility criteria
Treatment
Registry interventions
Randomized treatment groups and injection volumes
Treatment groupReported value
Onvuzosiran every 6 months“ADX-324 300 mg Q6M (1.5ml)”
Onvuzosiran every 3 months“ADX-324 240 mg Q3M (1.2ml)”
Placebo, larger volume“Placebo (1.5 ml) n=15”
Placebo, smaller volume“Placebo (1.2 ml) n=15”
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed

No evidence found.

Description of analysis sets
Analysis populations

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

No results are available. The trial began in August 2025, enrollment is ongoing, and the estimated primary completion date is November 2027, with topline data expected by the end of 2027. Planned enrollment is approximately 90 participants: 30 per onvuzosiran group and 30 receiving placebo, divided into two injection volumes of 15 participants each. This sample size limits the precision of safety estimates and of any subgroup analysis. The primary endpoint compares only the 300 mg every-6-months group with placebo; the 240 mg every-3-months comparison is a secondary endpoint. The controlled period lasts 25 weeks, so participants in the every-6-months group receive one active dose and the controlled data do not cover a second 6-month dosing interval. Attacks before Day 22 are excluded from the primary analysis, so the primary endpoint does not describe protection during the first 3 weeks after the first dose. The comparator is placebo, so the trial does not provide a direct comparison with an approved long-term prophylactic agent. Eligibility is limited to adults with type I or type II HAE who have at least 1 investigator-confirmed attack in the first 4 weeks of screening or at least 2 in 8 weeks, who complete washout of long-term prophylaxis, and who are judged able to use on-demand treatment alone; HAE with normal C1 inhibitor, clinically significant renal or hepatic disease, and prior RNA- or DNA-based HAE therapy are excluded. The doses were selected from pharmacodynamic data in healthy volunteers and from the attack-free intervals of 3 participants with HAE whose phase 2a doses were lower or less frequent than the phase 3 regimens. The design is described only in the registry record, ethics summaries, and sponsor documents; no peer-reviewed protocol publication was identified.

ADX-324-101

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Registry interventions
Part A: weight-based cohorts in the pharmacokinetic figure
Study outcomes
Rationale for using adverse event incidence as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Part A: participants by total dose group in the pharmacodynamic figure
Total dose groupGroup as printed
Placebo“ph1, 0 mg (n=11)”
Above 0 to 100 mg“ph1, >0-100 mg (n=13)”
Above 100 to 200 mg“ph1, >100-200 mg (n=8)”
Above 200 to 250 mg“ph1, >200-250 mg (n=6)”
Above 250 to 300 mg“ph1, >250-300 mg (n=3)”
Above 300 to 350 mg“ph1, >300-350 mg (n=4)”
Above 350 mg“ph1, >350 mg (n=4)”
300 mg plus or minus 25 mg“ADX-324 300 mg +/- 25 mg (n=5)”
Description of analysis sets
Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Study limitations
Summary

Part A enrolled healthy volunteers aged 18 to 55 years with a body mass index of 18 to 30 kg/m2, so its pharmacodynamic and safety findings come from a population without HAE. Its dose groups were small: the AAAAI poster lists 3 to 13 participants per total dose group, 5 participants in the 300 mg plus or minus 25 mg group, and the prospectus reports the 6 mg/kg results for 4 participants, 3 of whom were below LLOQ at nadir.

Part B was open-label and uncontrolled and enrolled 3 participants, one of whom withdrew for administrative reasons. Its doses (122.5 mg or 245 mg every 6 months) differ from the phase 3 regimens of 300 mg every 6 months and 240 mg every 3 months. All phase 2a dosing was every 6 months, and the November 2026 presentation describes the 3-month attack-free result as an “Observed 100% Q3M attack-free rate in Phase 2a after the first dose”.

No baseline characteristics, baseline attack rates, on-treatment attack rates, or quality-of-life results were identified. Efficacy is reported as attack-free intervals of individual participants and as an association between attacks and the degree of prekallikrein-kallikrein reduction, and the prospectus figure marks the approximate time of full inhibition (about Day 22) and the point 3 months after the first dose. The proposed threshold differs between documents: “> 70%” in the workshop abstract and “>80%” in the prospectus and other sponsor documents.

The results are available only in congress abstracts, posters, press releases, a corporate presentation, and SEC filings. No peer-reviewed full article was identified, the registry record shows “No Results Posted”, and primary completion is estimated for 2027-12-31. The documents use data cutoffs from December 2024 to November 2026.

The documents report different numbers for Part A: 43 participants (32 onvuzosiran, 11 placebo) in 5 cohorts in the February 2026 release; 49 participants (38 onvuzosiran, 11 placebo) in the posters and the prospectus; and 5, 6, or 7 cohorts in different documents. The prospectus attributes the 94% nadir and 84% six-month reductions to the 6 mg/kg cohort, while the November 2026 presentation attributes them to 6 mg/kg on one page and to 300 mg plus or minus 25 mg on another. The first Part B dose is written as 122 mg, 122.5 mg, or approximately 125 mg.

Safety reporting gives one frequency, 28.9%, attached to headache and injection-site reaction in Part A, and no counts for creatine phosphokinase changes or liver enzyme increases. Serious adverse events are described variously as absent, absent when treatment-related, or absent when drug-related. No immunogenicity data and no electrocardiogram results were identified, although electrocardiogram change is a registry primary outcome.

ADX-324-302

Objective
Location and study date
UK research ethics committee opinion
Study design
Registry design details
FieldReported value
Allocation“Non-Randomized”
Interventional model“Parallel Assignment”
Masking“Double”
Eligibility criteria
Treatment
Registry interventions
InterventionReported description
ADX-324 Dose Level 1“siRNA duplex oligonucleotide”
ADX-324 Dose Level 2“siRNA duplex oligonucleotide”
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed

No evidence found.

Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary

No results are available. The extension began in April 2026 and has an estimated primary completion date of June 2030. Allocation is non-randomized and every participant receives onvuzosiran, so the extension has no concurrent control group for safety or attack-rate comparisons. The core-study assignment remains masked through alternating onvuzosiran and placebo injections in the every-6-months group; the extension itself is not blinded to active treatment. Enrollment is limited to participants who completed STOP-HAE, and participants with a negative reaction to study drug in STOP-HAE are excluded, so the extension population may under-represent participants who did not tolerate or did not continue onvuzosiran. The primary endpoint is the incidence and severity of treatment-emergent adverse events through Month 36, and the monthly attack rate is a secondary endpoint. Planned enrollment is approximately 90 participants, which limits the detection of uncommon adverse events. No statistical analysis plan or analysis population definitions have been published.

OASIS-HAE

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using HAE attack rate per four weeks as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual treated populations
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline demographics
CharacteristicReported value
Mean age, years (SD)“37 (14)”
Female, n (%)“48 (53)”
Efficacy results
Mean attack rate per four weeks: weeks 1–25 in the publication
Health-related quality of life and patient-reported outcomes
Angioedema Control Test: change from baseline and disease control at week 24
Safety results
Injection-site reactions
TreatmentParticipants, n (%)
Donidalorsen every four weeks, n=45“11 (24)”
Donidalorsen every eight weeks, n=23“1 (4)”
Placebo, n=22“1 (5)”
Study limitations
Summary

The trial treated 90 participants: 45 received donidalorsen every 4 weeks, 23 received donidalorsen every 8 weeks, and 22 received placebo. The randomized comparison does not describe outcomes beyond Week 25. The full analysis set comprised “all randomized patients who received at least 1 dose of Study Drug”, and attack counts were analyzed with a “Poisson regression model and Pearson chi-square scaling of standard errors”. The placebo group of 22 participants and the every-8-week group of 23 participants limit precision for between-group estimates and for uncommon adverse events; injection-site reactions occurred in 11 of 45 participants (24%) receiving every-4-week dosing. Donidalorsen was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, baseline attack rates, observation periods, and attack-rate definitions (attacks per 4 weeks in this trial) can affect the reported rates.

OASISplus

Objective
Location and study date
Registered study dates and enrollment status
FieldReported value
Study start“2022-07-13”
Primary completion, estimated“2026-12”
Study completion, estimated“2027-03”
Recruitment status“Active, not recruiting”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse event incidence as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
PopulationParticipants
Actual enrollment, both cohorts“154”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Open-label extension cohort: demographics and baseline attack rate
Switch cohort: demographics and baseline attack rate on prior prophylaxis
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Open-label extension cohort: treatment-emergent adverse events at year 1
Switch cohort: treatment-emergent adverse events at year 1
Study limitations
Summary

OASISplus is an open-label study with no comparator group, and both cohort publications summarized outcomes with descriptive statistics and no formal sample size calculation.

The open-label extension cohort enrolled 83 of the 90 OASIS-HAE participants (69 receiving donidalorsen every 4 weeks and 14 every 8 weeks). Participants continued every-8-week dosing only if they had been attack-free during the last 8 weeks of OASIS-HAE, so the every-8-week group of 14 participants was selected for response. The 94% and 95% reductions are measured from the OASIS-HAE baseline, before any prophylaxis in that trial.

The Switch cohort dosed 64 participants who had been receiving lanadelumab (31), berotralstat (11), or C1 inhibitor (22). Its attack-rate baseline was the screening period on the prior prophylactic treatment (mean 0.85 attacks per month), so the 67.6% reduction is a within-participant comparison with continued prior prophylaxis, without randomization or blinding. Eleven participants (16.9%) discontinued during the first year, including 4 who had switched from lanadelumab and discontinued for lack of efficacy. The subgroups by prior therapy contain 11 to 31 participants, which limits precision for comparisons between them.

In both cohorts, 89.1% to 91.6% of participants were White. The registry lists an actual enrollment of 154 participants across the study, and the two cohort publications report 83 and 65 participants enrolled. The year 1 publications report data through January 27, 2025, and the registry lists treatment for up to 157 weeks, with primary completion estimated for December 2026.

HELP

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Subcutaneous lanadelumab regimens; placebo comparator
RegimenDose and interval
Lower-dose monthly“150 mg q4wks”
Higher-dose monthly“300 mg q4wks”
Every two weeks“300 mg q2wks”
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized treatment groups
GroupParticipants
Lanadelumab 150 mg every four weeks“28”
Lanadelumab 300 mg every four weeks“29”
Lanadelumab 300 mg every two weeks“27”
Placebo“41”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Age at baseline
Efficacy results
Mean monthly attack rate over 26 weeks
TreatmentAttacks per month
Lanadelumab 150 mg every four weeks“0.48”View highlighted excerpt for this quote
Lanadelumab 300 mg every four weeks“0.53”View highlighted excerpt for this quote
Lanadelumab 300 mg every two weeks“0.26”View highlighted excerpt for this quote
Placebo“1.97”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Participants achieving the AE-QoL minimal clinically important difference
PopulationProportion
All lanadelumab regimens pooled“70%”
Placebo“37%”
Lanadelumab 300 mg every two weeks“81%”
Safety results
Injection-site reactions
TreatmentParticipants, n (%)
Lanadelumab 150 mg every four weeks, n=28“16 (57)”
Lanadelumab 300 mg every four weeks, n=29“13 (45)”
Lanadelumab 300 mg every two weeks, n=27“15 (56)”
Placebo, n=41“14 (34)”
Study limitations
Summary

The trial randomized 125 participants to three lanadelumab regimens (28, 29, and 27 participants) or placebo (41 participants), and 113 (90.4%) completed the study. The primary analysis used the “Intent-to-Treat” population and a “Poisson regression model”. Because three active regimens shared the randomization, each lanadelumab group contained 27 to 29 participants, which limits precision for comparisons between regimens and for uncommon adverse events; injection-site reactions were reported in 45% to 57% of lanadelumab groups and in 34% of the placebo group. The placebo-controlled period does not describe outcomes over longer treatment. Lanadelumab was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, run-in requirements, baseline attack rates, and observation periods can affect the reported attack rates.

VANGUARD

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized and included populations
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline sex distribution
Efficacy results
Published monthly attack rates and relative treatment effect
OutcomeReported value
Garadacimab: mean monthly attack rate“0·27”View highlighted excerpt for this quote
Placebo: mean monthly attack rate“2·01”View highlighted excerpt for this quote
Difference in means, percent“-87%”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Safety results
Nasopharyngitis adverse reactions
TreatmentParticipants, n (%)
Garadacimab, n=39“8 (21)”
Placebo, n=25“3 (12)”
Study limitations
Summary

Of 65 randomized participants, 64 were included in the reported comparison (39 receiving garadacimab and 25 receiving placebo) after one participant was randomized in error. Allocation was 3:2 across 28 centers, and the placebo group of 25 participants limits precision for between-group estimates and for uncommon adverse events. Eligibility required “two or more acute HAE attacks”. The primary endpoint, the number of HAE attacks per month, does not describe outcomes over longer treatment. No health-related quality of life result for this trial was identified. Garadacimab was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, run-in requirements, baseline attack rates, and observation periods can affect the reported attack rates.

APeX-2

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using monthly HAE attack rate as the primary endpoint

Not applicable.

Statistical analysis description
Number of participants (Planned and analyzed)
Randomized and treated populations
Description of analysis sets
Results
Participant disposition
Treatment exposure
Baseline characteristics
Median baseline attack rate during the prospective run-in period
Efficacy results
Monthly attack rates during the 24-week comparison
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary

The trial randomized 121 participants at 40 sites in 11 countries and treated 120: 41 received berotralstat 110 mg, 40 received berotralstat 150 mg, and 39 received placebo. Eligibility required “at least two investigator-confirmed attacks” during the run-in period, and the median baseline attack rate was 2.9 attacks per month. Efficacy was analyzed in the intent-to-treat population with a “negative binomial regression model”. The comparison does not describe outcomes over longer treatment, and groups of 39 to 41 participants limit precision for uncommon adverse events. No health-related quality of life result for this trial was identified. Berotralstat was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, baseline attack rates, and observation periods can affect the reported attack rates.

COMPACT

Objective
Location and study date
Trial locations and global end date
FieldReported value
Planned region“Argentina”
Planned region“Australia”
Planned region“Canada”
Planned region“European Union”
Planned region“United States”
Global end of trial“2015-10-12”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using HAE attack frequency as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
Actual randomization
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline age
CharacteristicReported value
Median age, years (range)“40 (12 to 72)”
Efficacy results
Monthly attack-rate differences versus placebo
RegimenMean difference, attacks per month
40 IU/kg twice weekly“-2.42”View highlighted excerpt for this quote
60 IU/kg twice weekly“-3.51”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Safety results
Study limitations
Summary

The crossover trial randomized 90 participants against a planned enrollment of 100, and 79 participants completed it. Each participant received active treatment and placebo in sequence, and efficacy was evaluated “for the last 14 weeks of each treatment period” of the 32-week study, so period and carryover effects can influence the estimates. The efficacy results reported for this trial are mean differences from placebo in monthly attack rate (-2.42 attacks per month with 40 IU/kg and -3.51 with 60 IU/kg twice weekly), which are not directly comparable with absolute attack rates reported for parallel-group designs. No health-related quality of life result for this trial was identified. The trial enrolled participants aged 12 years or older, with a median age of 40 years (range, 12 to 72). Subcutaneous C1 inhibitor was compared with placebo only, so comparison with other prophylactic agents relies on cross-trial comparison.